The objective of this study is to evaluate the safety and preliminary biologic
activity/efficacy of X-82 in patients with wet Age-related Macular Degeneration (AMD).
Preliminary efficacy will be assessed by change from baseline in visual acuity, fluorescein
leakage, retinal thickness and fibrosis, if detectable, based on fundus examination, fundus
photography, fluorescein angiography and optical coherence tomography (OCT).